[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperparathyroidism-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperparathyroidism-primary":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,103,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100559342","patient-navigation-to-improve-surgical-access-in-primary-hyperparathyroidism-100559342",false,"NCT06562881","Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism","Inclusion Criteria:\n\n* Diagnosed with PHPT and not yet had parathyroidectomy who meet criteria for surgical treatment of PHPT (osteoporosis, fragility fracture, or evidence of vertebral compression fracture on spine imaging, renal involvement \\[renal stone, silent nephrolithiasis on renal imaging, nephrocalcinosis, hypercalciuria (24-hour urine calcium level 400 mg\u002FdL) with increased stone risk, or impaired renal function (glomerular filtration rate 60 mL\u002Fmin)\\], calcium 1 mg\u002FdL above upper limit of normal, age less than 50)\n* Qualify as a member of a racial or ethnic minority group (Black, Hispanic, Asian and Pacific Islander, Native American), lower socioeconomic neighborhoods (by zipcode), socially vulnerable (social determinants of health indicating financial strain, social vulnerability index in the top quartile 75%+ by zip code), or with underinsurance (Medicaid, Medicare, dual eligible, uninsured)\n\nExclusion Criteria:\n\n* Prior Parathyroidectomy\n* End-stage Renal Disease\n* Renal Transplant\n* Vitamin D Deficiency\n* Metastatic Disease\n* Familial Hypocalciuric Hypercalcemia\n* No Indication for Surgery\n* Unable\u002FUnwilling to provide consent","ALL","18 Years",{"count":18,"type":19},76,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this study is to address surgical health equity in historically marginalized participants with primary hyperparathyroidism (PHPT). The main questions that this study aims to answer are, how does patient navigation impact:\n\n* The proportion of PHPT participants undergo parathyroidectomy?\n* The proportion of PHPT participants who complete surgical consultation?\n* Time to surgical consultation?\n* Time to surgery?",[25],"Hyperparathyroidism, Primary",[27,28],"Parathyroidectomy","Barriers and Challenges to Surgical Health Equity","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":19},"2026-07-01",{"date":37,"type":19},"2026-12-30",{"name":39,"class":40},"University of Pennsylvania","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100600585","parathyroid-adenoma-detection-with-rubidium-82-imaging-100600585","NCT07099404","Parathyroid Adenoma Detection With Rubidium-82 Imaging","Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study","PARAGON","Inclusion Criteria:\n\n1. Age ≥ 18y\n2. Ability to undergo imaging logistics\n3. Ability to provide informed consent\n4. Biochemical evidence of primary hyperparathyroidism\n5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging\n\nExclusion Criteria:\n\n1. Normocalcemic primary hyperparathyroidism\n2. Breastfeeding or pregnancy\n3. Claustrophobia or inability to undergo imaging logistics\n4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study",{"count":51,"type":19},20,"OBSERVATIONAL","Assess the uptake of rubidium-82 in parathyroid adenomas.",[55,25],"Parathyroid Adenomas",[57],"Parathyroid adenomas, Rubidium-82","NOT_YET_RECRUITING","2025-08-18",{"date":61,"type":33},"2025-08-22",{"date":63,"type":19},"2025-11",{"date":65,"type":19},"2028-09",{"name":67,"class":40},"Matthieu Pelletier-Galarneau, MD MSc",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":41},"100596250","white-cap-intra-operative-parathyroid-tissue-sensor-pts-guided-assessment-of-parathyroid-viability-and-surgical-decision-making-100596250","NCT07043010","WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making","WHITE CAP Trial: Optical Parathyroid Tissue Sensor-Guided Assessment of Parathyroid Viability and Its Impact on Clinical Decision-Making","WHITE CAP-PTS","Inclusion Criteria:\n\n* Age 18 to 75 years, able to give informed consent.\n* Biochemically proven primary hyperparathyroidism (elevated serum calcium and inappropriately high PTH).\n* Pre-operative imaging (sestamibi scan, 4-phase CT, or ultrasound) concordant with a single parathyroid adenoma.\n* Planned minimally invasive parathyroidectomy using near-infrared parathyroid tissue sensor (PTS) guidance.\n\nExclusion Criteria:\n\n* Multiple endocrine neoplasia (MEN 1 or 2) or suspicion of multi-gland disease (\\>1 enlarged gland on imaging).\n* Prior parathyroid or extensive neck surgery causing distorted anatomy.\n* Need for simultaneous total thyroidectomy or other major neck procedure.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n* Pregnancy or breastfeeding.\n* Inability to tolerate general anaesthesia or contraindication to intra-operative PTS imaging.","75 Years",{"count":79,"type":19},120,[22],"Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still \"glows\" under a near-infrared parathyroid tissue sensor (PTS). It is unclear whether keeping this tissue in place helps preserve hormone function or whether it leaves behind cells that could become over-active again.\n\nThe WHITE CAP study will compare two common surgical choices:\n\nPreservation strategy - the surgeon removes only the adenoma and leaves the glowing rim of normal tissue untouched.\n\nEn-bloc strategy - the surgeon removes the adenoma together with the glowing rim; if too little parathyroid tissue remains, a small fragment is transplanted into the forearm muscle.\n\nAbout 120 adult patients who have a single parathyroid adenoma will be randomly assigned (like tossing a coin) to one of the two strategies. All operations will use the same FDA-cleared PTS camera that shows the glands in real time without dye or radiation.\n\nThe main question is whether preserving the normal rim lowers the rate of temporary low blood-calcium (numbness, tingling) during the first two days after surgery. The study will also check long-term results-blood calcium and parathyroid hormone (PTH) levels, symptoms, and any return of the disease-over two years.\n\nThe PTS imaging itself is painless and adds only a few minutes to the operation. Risks are the same as for standard parathyroid surgery, and participants can withdraw at any time without affecting their usual care.",[25,83,84,85],"Parathyroid Neoplasms","Parathyroid Adenoma","Hypocalcemia",[87,88,89,90,91,92,93],"Near-Infrared Autofluorescence","Parathyroid Tissue Sensor","Parathyroid Viability","Peri-adenoma Rim Preservation","Intra-operative Imaging","Calcium Homeostasis","PTS Camera","2025-06-27",{"date":96,"type":33},"2025-06-29",{"date":98,"type":19},"2025-07-01",{"date":100,"type":19},"2029-12-31",{"name":102,"class":40},"Fujian Medical University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":20,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100533789","autofluorescence-in-surgery-for-primary-hyperparathyroidism-100533789","NCT06230380","Autofluorescence in Surgery for Primary Hyperparathyroidism","Use of Intraoperative Autofluorescence Imaging in Surgery for Primary Hyperparathyroidism - a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age\\>18 years and able to give informed consent.\n* A diagnosis of PHPT.\n* Planned exploratory PTX with ioPTH measurement.\n\nExclusion Criteria:\n\n* Concordant high-confidence imaging; planned focused\u002Fselective PTX\n* Previous thyroid or parathyroid surgery.\n* Planned simultaneous thyroid surgery.\n* MEN, lithium induced hyperparathyroidism.\n* eGFR \\\u003C 30.\n* Kidney transplant.",{"count":111,"type":19},100,[22],"The study aims to test if autofluorescence imaging (AF) is a useful surgical aid during parathyroidectomy (PTX) for primary hyperthyroidism (PHPT).",[25],"2025-01-27",{"date":117,"type":33},"2025-01-29",{"date":119,"type":33},"2024-01-01",{"date":121,"type":19},"2026-06-01",{"name":123,"class":40},"Aarhus University Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":41},"100482013","the-bone-parathyroid-crosstalk-in-primary-hyperparathyroidism-100482013","NCT05556499","The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism","Interactions Between Bone and Parathyroid Tumors in Patiens With Primary Hyperparathyroidism (The PARABONE Study)","PARABONE","Inclusion Criteria:\n\nInclusion criteria for the HPT patient group:\n\n* diagnosis of primary hyperparathyroidism according to the most recent guidelines \\[Marcocci et al. 2015\\];\n* adult patients (age ≥ 18 years);\n* signature of the informed consent.\n\nInclusion criteria for the HPT-PTX patient group:\n\n* diagnosis of primary hyperparathyroidism with indication of surgical removal of the parathyroid tumor according to the most recent guidelines \\[Marcocci et al. 2015\\];\n* adult patients (age ≥18 years);\n* signature of the informed consent.\n\nExclusion Criteria:\n\n* Criteria for exclusion from the study are:\n* age \\\u003C18 years\n* diagnosis of hyperparathyroidism secondary to chronic renal failure or to vitamin D or calcium deficiency;\n* pregnancy or breastfeeding (self-declaration)\n* lack of informed consent",{"count":111,"type":19},"The PARABONE study aims to investigate the interaction between bone and parathyroid glands in patients with primary hyperparathyroidism (HPT). The study consists of a clinical part aimed at evaluating a series of circulating molecules of bone derivation (osteocalcin, molecules of the WNT pathway, RANKL, osteoprotegerin, Scelrostin, FGF23) in patients with HPT. In particular, the study has as its primary objective to identify the correlation between circulating levels of PTH and levels of GlaOC and GluOC in patients with HPT.",[25,135,83],"Osteoporosis","2022-09-28",{"date":138,"type":33},"2022-09-30",{"date":140,"type":19},"2022-10",{"date":142,"type":19},"2026-06-24",{"name":144,"class":40},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio"]